PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
PD-L1(+) 巨噬细胞抑制 T 细胞介导的抗癌免疫
英文原题：PD-L1(+) macrophages suppress T cell-mediated anticancer immunity.
查看英文原题
PD-L1(+) macrophages suppress T cell-mediated anticancer immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
最近，我们发现基于自体DC的疫苗会在肿瘤和肿瘤引流淋巴结中诱导免疫抑制性PD-L1+肿瘤相关巨噬细胞（TAM）增加，从而削弱治疗性免疫的效果。只有将DC疫苗与抗PD-L1免疫检查点抑制联合使用，而非单独使用靶向PD-1的抗体，才能在小鼠中启动CD8+细胞毒性T淋巴细胞（CTL）介导的肿瘤抑制。总之，我们阐明了一种基于PD-L1检查点阻断的策略，以避免DC疫苗治疗期间TAM诱导的T细胞耗竭。
展开英文摘要原文
Recently, we showed that an autologous DC-based vaccine induces an increase in immunosuppressive PD-L1 + tumor-associated macrophages (TAM) both in the tumor and the tumor draining lymph nodes, thereby blunting the efficacy of therapeutic immunization.
Only the combination of the DC vaccine with anti-PD-L1 immune checkpoint inhibition, but not the use of antibodies targeting PD-1 alone, was able to set off CD8 + cytotoxic T lymphocyte (CTL)-mediated tumor suppression in mice. In sum, we delineated a PD-L1 checkpoint blockade-based strategy to avoid TAM-induced T cell exhaustion during DC vaccine therapy.
论文信息
- 作者
- Liu P、Zhao L、Kroemer G、Kepp O
- 单位
- Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.France
- 期刊
- Oncoimmunology2024
- 原文标识
- PubMed 38590800 · DOI 10.1080/2162402X.2024.2338951
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →